Open Access. Powered by Scholars. Published by Universities.®

Hemic and Lymphatic Diseases Commons™

Open Access. Powered by Scholars. Published by Universities.®

551 Full-Text Articles 3,763 Authors 194,316 Downloads 55 Institutions

All Articles in Hemic and Lymphatic Diseases

Faceted Search

551 full-text articles. Page 5 of 27.

Exploring Intracellular Signaling Responses To Ks18, A Potent Mcl-1 Inhibitor, In Multiple Myeloma, Emily Nelson, Omar S Al-Odat, Dhruti A. Brahmbhatt, Tulin Budak-Alpdogan, Subash Jonnalagadda, Manoj Kumar Pandey 2025 Rowan University

Exploring Intracellular Signaling Responses To Ks18, A Potent Mcl-1 Inhibitor, In Multiple Myeloma, Emily Nelson, Omar S Al-Odat, Dhruti A. Brahmbhatt, Tulin Budak-Alpdogan, Subash Jonnalagadda, Manoj Kumar Pandey

Rowan-Virtua Research Day

Multiple myeloma (MM), a cancer of plasma B cells, is a hematological malignancy in which patients inevitably relapse and develop drug resistance. Mcl-1, a member of the anti-apoptotic subgroup of Bcl-2 family proteins, plays a critical role in the progression of multiple myeloma and contributes significantly to drug resistance. Elevated Mcl-1 expression is observed in approximately 52% of MM patients at diagnosis, increasing to 81% at relapse. Given its driving role in disease progression and therapy resistance, Mcl-1 inhibition has emerged as a promising therapeutic target, prompting ongoing research into the development and clinical evaluation of Mcl-1 inhibitors, particularly for …


Reviewing The Effect Of Antiplatelet Therapy On Lumbar Puncture Complications, John Andre Socci 2025 Rowan University

Reviewing The Effect Of Antiplatelet Therapy On Lumbar Puncture Complications, John Andre Socci

Rowan-Virtua Research Day

Reviewing The Effect of Antiplatelet Therapy on Lumbar Puncture Complications aims to assess literature that discusses the possible risks of undergoing lumbar puncture while on antiplatelet therapy. Lumbar punctures offer vital information that can help guide making accurate diagnosis and creating appropriate treatment plans. However, a large portion of the population is on antiplatelet therapy for cardiovascular and cerebrovascular disease prevention. While there are many benefits to being on these medicines, patients are at increased risk for bleeding. Thus the clinical question as to whether or not proceed with lumbar puncture on patients taking antiplatelet therapy involves weighing risks and …


Ks151 Synergizes With Venetoclax And Abt-737 In Aml: Efficacy In Both Flt3-Wildtype And Flt3-Mutant Models, Sahil Jethi, Arnold Rojas, Omar S. Al-Odat, Krishne Gowda, Subash C. Jonnalagadda, Manoj Pandey 2025 Rowan University

Ks151 Synergizes With Venetoclax And Abt-737 In Aml: Efficacy In Both Flt3-Wildtype And Flt3-Mutant Models, Sahil Jethi, Arnold Rojas, Omar S. Al-Odat, Krishne Gowda, Subash C. Jonnalagadda, Manoj Pandey

Rowan-Virtua Research Day

Acute myeloid leukemia (AML) is the most common leukemia in adult patients, with a 5-year survival rate of less than 30 percent. Therefore, more effective therapeutic strategies are required to prolong the survival of AML patients. Importantly, anti-apoptotic proteins, especially B-cell lymphoma 2 (Bcl-2), overexpression in AML is associated with uncontrolled growth as well as chemoresistance. Unsurprisingly, Bruton’s tyrosine kinase (BTK) overexpresses in AML and associated with poor prognosis and chemoresistance. The FDA-approved BTK inhibitor, ibrutinib, has been successful in treating other hematologic malignancies, but a proportion of patients relapse mainly because of acquired mutations at Cys481Ser (C481S) in the …


Long Term Results Of Venetoclax Combined With Flag-Ida Induction And Consolidation For Newly Diagnosed And Relapsed Or Refractory Acute Myeloid Leukemia, Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi, Tapan M Kadia, Sanam Loghavi, Lianchun Xiao, Ghayas C Issa, Nicholas J Short, Koji Sasaki, Sa A Wang, Jillian K Mullin, Sherry Pierce, Corey Bradley, Gautam Borthakur, Abhishek Maiti, Yesid Alvarado, Naveen Pemmaraju, Alessandra Ferrajoli, Mahesh Swaminathan, Maro Ohanian, Hussein A Abbas, Danielle Hammond, Jan Burger, Fadi Haddad, Guillermo Montalban-Bravo, Kelly Chien, Lucia Masarova, Musa Yilmaz, Nitin Jain, Michael Andreeff, Guillermo Garcia-Manero, Steven Kornblau, Farhad Ravandi, Elias Jabbour, Marina Y Konopleva, Hagop M Kantarjian 2025 The Texas Medical Center Library

Long Term Results Of Venetoclax Combined With Flag-Ida Induction And Consolidation For Newly Diagnosed And Relapsed Or Refractory Acute Myeloid Leukemia, Courtney D Dinardo, Wei-Ying Jen, Koichi Takahashi, Tapan M Kadia, Sanam Loghavi, Lianchun Xiao, Ghayas C Issa, Nicholas J Short, Koji Sasaki, Sa A Wang, Jillian K Mullin, Sherry Pierce, Corey Bradley, Gautam Borthakur, Abhishek Maiti, Yesid Alvarado, Naveen Pemmaraju, Alessandra Ferrajoli, Mahesh Swaminathan, Maro Ohanian, Hussein A Abbas, Danielle Hammond, Jan Burger, Fadi Haddad, Guillermo Montalban-Bravo, Kelly Chien, Lucia Masarova, Musa Yilmaz, Nitin Jain, Michael Andreeff, Guillermo Garcia-Manero, Steven Kornblau, Farhad Ravandi, Elias Jabbour, Marina Y Konopleva, Hagop M Kantarjian

Faculty, Staff and Student Publications

Intensive chemotherapy remains the standard for newly diagnosed (ND) acute myeloid leukemia (AML); however, relapse risk remains high. Additionally, most patients with relapsed/refractory (RR) AML have poor outcomes. We report the long-term experience of 138 patients, 77 ND and 61 RR, treated with FLAG-IDA in combination with venetoclax. In the ND cohort, the overall response rate (ORR) was 97%, with a composite complete remission (CRc) rate of 95% and undetectable measurable residual disease (MRD) status by flow cytometry in 90%. The 3-year OS and EFS rates were 66 and 64%, respectively. Outcomes were similar across European LeukemiaNet (ELN) 2022 risk …


Oral Decitabine Cedazuridine With And Without Venetoclax In Higher-Risk Myelodysplastic Syndromes Or Chronic Myelomonocytic Leukemia: A Propensity Score-Matched Study, Alex Bataller, Koji Sasaki, Samuel Urrutia, Guillermo Montalban-Bravo, Alexandre Bazinet, Danielle Hammond, Mahesh Swaminathan, Ghayas Issa, Nicholas Short, Naval Daver, Courtney D DiNardo, Tapan Kadia, Elias Jabbour, Farhad Ravandi, Gail J Roboz, Michael Savona, Elizabeth A Griffiths, James McCloskey, Olatoyosi Odenike, Aram Oganesian, Harold N Keer, Mohammad Azab, Hagop Kantarjian, Guillermo Garcia-Manero 2025 The Texas Medical Center Library

Oral Decitabine Cedazuridine With And Without Venetoclax In Higher-Risk Myelodysplastic Syndromes Or Chronic Myelomonocytic Leukemia: A Propensity Score-Matched Study, Alex Bataller, Koji Sasaki, Samuel Urrutia, Guillermo Montalban-Bravo, Alexandre Bazinet, Danielle Hammond, Mahesh Swaminathan, Ghayas Issa, Nicholas Short, Naval Daver, Courtney D Dinardo, Tapan Kadia, Elias Jabbour, Farhad Ravandi, Gail J Roboz, Michael Savona, Elizabeth A Griffiths, James Mccloskey, Olatoyosi Odenike, Aram Oganesian, Harold N Keer, Mohammad Azab, Hagop Kantarjian, Guillermo Garcia-Manero

Faculty, Staff and Student Publications

Hypomethylating agents (HMA) are indicated in the treatment of higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The combination of hypomethylating agents with venetoclax (Ven) has demonstrated promising results in these diseases, although randomized clinical trials are needed for validation. In this retrospective study, we compared two matched cohorts of patients with MDS or CMML: one receiving oral decitabine-cedazuridine (DEC-C, n = 73) and one receiving DEC-C and Ven (DEC-C-Ven, n = 51), in three contemporary clinical trials. The aim is to determine the impact of the addition of Ven to HMA in MDS and CMML. Individuals were matched …


Outcomes In Patients With Classic Hodgkin Lymphoma Refractory Or Intolerant To Brentuximab Vedotin And Anti-Pd-1 Therapy: A Real World Analysis From 15 U.S. Academic Centers, Timothy J. Voorhees, Eric M. McLaughlin, Pallawi Torka, Jorge Florindez, Na Hyun Kim, Tamara K. Moyo, Heather Reves, Nuttavut Sumransub, Saarang Deshpande, Ashley Rose, Cassandra Duarte, Muhammad Salman Faisal, Showkat Hamid, Suki Subbiah, Sabarish Ayyappan, Lauren Shea, Matt Cortese, Krish Patel, Ajay Major, Hayder Saeed, Jakub Svoboda, Sanjal Desai, Praveen Ramakrishnan Geethakumari, Mehdi Hamadani, Natalie Grover, Narendranath Epperla 2025 The Ohio State University, Columbus, OH

Outcomes In Patients With Classic Hodgkin Lymphoma Refractory Or Intolerant To Brentuximab Vedotin And Anti-Pd-1 Therapy: A Real World Analysis From 15 U.S. Academic Centers, Timothy J. Voorhees, Eric M. Mclaughlin, Pallawi Torka, Jorge Florindez, Na Hyun Kim, Tamara K. Moyo, Heather Reves, Nuttavut Sumransub, Saarang Deshpande, Ashley Rose, Cassandra Duarte, Muhammad Salman Faisal, Showkat Hamid, Suki Subbiah, Sabarish Ayyappan, Lauren Shea, Matt Cortese, Krish Patel, Ajay Major, Hayder Saeed, Jakub Svoboda, Sanjal Desai, Praveen Ramakrishnan Geethakumari, Mehdi Hamadani, Natalie Grover, Narendranath Epperla

School of Medicine Faculty Publications

Anti-PD-1 based therapies and brentuximab vedotin (BV) have significantly improved survival in patients with classic Hodgkin lymphoma (cHL) and have been incorporated into earlier lines of therapy. However, there is insufficient data regarding the clinical outcomes in patients who develop refractory disease or who become intolerant of BV and anti-PD-1 therapies (double refractory/intolerant; DR/INT). Here, we evaluated outcomes in patients with DR/INT cHL from 15 US academic medical centers. A total of 173 patients were identified as DR/INT. The median overall survival from the time of cHL diagnosis (OS-1) was 14.8 years (95% CI: 10.9–20.9 years) and the 10-year OS-1 …


Cryptic Kmt2a::Afdn Fusion Due To Afdn Insertion Into Kmt2a In A Patient With Acute Monoblastic Leukemia, Qing Wei, Gokce A Toruner, Beenu Thakral, Keyur P Patel, Naveen Pemmaraju, Rashmi Kanagal-Shamanna, Ghayas C Issa, Sanam Loghavi, L Jeffrey Medeiros, Courtney DiNardo 2025 The Texas Medical Center Library

Cryptic Kmt2a::Afdn Fusion Due To Afdn Insertion Into Kmt2a In A Patient With Acute Monoblastic Leukemia, Qing Wei, Gokce A Toruner, Beenu Thakral, Keyur P Patel, Naveen Pemmaraju, Rashmi Kanagal-Shamanna, Ghayas C Issa, Sanam Loghavi, L Jeffrey Medeiros, Courtney Dinardo

Faculty, Staff and Student Publications

Background: KMT2A rearrangements occur in ~10% of acute myeloid leukemia (AML) cases and are critical for classification, risk stratification, and use of targeted therapy. However, insertions involving the KMT2A gene can evade detection using chromosomal analysis and/or fluorescence in situ hybridization (FISH).

Methods: We present a case of a 22-year-old woman with acute monoblastic leukemia harboring a cryptic KMT2A::AFDN fusion identified by RNA sequencing. Initial FISH showed a 3' KMT2A deletion, while conventional karyotyping and the automated bioinformatic pipeline for optical genome mapping (OGM) did not identify the canonical translocation.

Results: To resolve these discrepancies, metaphase KMT2A FISH (break-apart fusion …


Atypical Dengue Fever With Severe Hematological Manifestations: A Case From The Rio Grande Valley, Elias Arellano Villanueva, Alhasan Asaad, Jose Campo Maldonado 2025 The University of Texas Rio Grande Valley

Atypical Dengue Fever With Severe Hematological Manifestations: A Case From The Rio Grande Valley, Elias Arellano Villanueva, Alhasan Asaad, Jose Campo Maldonado

Research Symposium

Background: Dengue fever, a mosquito-borne viral illness, is endemic in tropical regions, including border regions like the Rio Grande Valley while often self-limited, severe presentations such as dengue hemorrhagic fever and dengue shock syndrome highlight its challenges and complexities. This report describes an atypical dengue case with severe hematological manifestations, underscoring the diagnostic challenges and the importance of early recognition, multidisciplinary evaluation, and evidence-based management.

Case Presentation: A 22-year-old Hispanic female with no significant past medical history presented to the ED with hematemesis and fever following her travel to Monterrey, Mexico. Initial symptoms included high fever (107.6°F), chills, diarrhea, vomiting, …


Hypoalbuminemia And Postoperative Outcomes Following Major Salivary Gland Resection, Praneet C. Kaki, Aman M. Patel, Jason A. Brant, Steven B. Cannady, Karthik Rajasekaran, Robert M. Brody, Ryan M. Carey 2025 Thomas Jefferson University

Hypoalbuminemia And Postoperative Outcomes Following Major Salivary Gland Resection, Praneet C. Kaki, Aman M. Patel, Jason A. Brant, Steven B. Cannady, Karthik Rajasekaran, Robert M. Brody, Ryan M. Carey

SKMC Student Presentations and Publications

OBJECTIVE: Hypoalbuminemia (HA) is a proxy for malnutrition that has been associated with postoperative complications in several surgical subspecialties. This study investigates the association between pre-operative HA and complications following major salivary gland (MSG) resection.

METHODS: Patients undergoing outpatient, elective MSG resection were extracted from the 2005 to 2020 National Surgical Quality Improvement Program database. Demographics and comorbidities were compared between HA (preoperative serum albumin < 3.5 g/dL) and non-HA cohorts. To determine associations between albumin status and postoperative complications, univariate and multivariable binary logistic regression analyses were performed.

RESULTS: A total of 5774 patients undergoing MSG resection were included, of which 321 (5.6%) had preoperative HA. HA was associated with older age on univariate analysis (65.2 vs. 60.2 years,

CONCLUSION: Preoperative HA may …


An Atypical Case Of Epec-Hus In An Adult, Rabia S. Mahfooz, Annmary Behanan, Babivigasan Gunasegaran, Amita J. Dsouza 2025 HCA Healthcare

An Atypical Case Of Epec-Hus In An Adult, Rabia S. Mahfooz, Annmary Behanan, Babivigasan Gunasegaran, Amita J. Dsouza

Gulf Coast Division GME Research Day 2025

No abstract provided.


Atypical Presentation Of Cd4+ Small/Medium T-Cell Lymphoproliferative Disorder, Rafael do Valle, Reem Ayoub, Marshall Hall, Henry Lim, Christian Scheufele, Garrett Furth, Michael Carletti, Stepehen E. Weis 2025 UNTHSC

Atypical Presentation Of Cd4+ Small/Medium T-Cell Lymphoproliferative Disorder, Rafael Do Valle, Reem Ayoub, Marshall Hall, Henry Lim, Christian Scheufele, Garrett Furth, Michael Carletti, Stepehen E. Weis

North Texas Research Forum 2025

Introduction: Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (PCSM-LPD) is a rare cutaneous disorder that until 2016, was classified as a primary cutaneous lymphoma. PCSM-LPD histopathologically consists of a localized proliferation of small to medium-sized T lymphocytes. Clinically there is minimal to no systemic involvement. It typically presents as an asymptomatic, solitary red-purple nodule, papule, or plaque on the face. PCSM-LPD has an indolent course and an excellent prognosis. It is important to recognize PCSM-LPD as a distinct entity from primary cutaneous lymphoma to avoid treatments with side effects. Case Presentation: A 68-year-old female with a history of insulin-dependent type …


Fatal Streptococcal Pneumonia Bacteremia Complicated By Purpura Fulminans In An Asplenic Patient, Farigol Hakem Zadeh, Nikita Shah, Vidya S. Kollu 2025 HCA Healthcare

Fatal Streptococcal Pneumonia Bacteremia Complicated By Purpura Fulminans In An Asplenic Patient, Farigol Hakem Zadeh, Nikita Shah, Vidya S. Kollu

North Florida Division GME Research Day 2025

No abstract provided.


Acute Respiratory Compromise Secondary To Superior Vena Cava Syndrome In A Sickle Cell Patient. Vaso-Occlusion Triggered By Steroids?, Ashley Diaz, Priya Mohan, Abhishek Sharma, David Zarabanda, Raiko Diaz 2025 HCA Healthcare

Acute Respiratory Compromise Secondary To Superior Vena Cava Syndrome In A Sickle Cell Patient. Vaso-Occlusion Triggered By Steroids?, Ashley Diaz, Priya Mohan, Abhishek Sharma, David Zarabanda, Raiko Diaz

East Florida Division GME Research Day 2025

No abstract provided.


Effective Managment Of Relapsing Henoch-Schonlein Purpura With Nephropathy In An Adult With Long-Term Use Of Azathioprine, Rabia S. Mahfooz, Neil Maithel, Loiacono Agostina, Minha Aslam, Naser Elkhalili 2025 HCA Healthcare

Effective Managment Of Relapsing Henoch-Schonlein Purpura With Nephropathy In An Adult With Long-Term Use Of Azathioprine, Rabia S. Mahfooz, Neil Maithel, Loiacono Agostina, Minha Aslam, Naser Elkhalili

Gulf Coast Division GME Research Day 2025

No abstract provided.


A Rare Presentation Of Prothrombin G20210a Mutation As A Right Ventricular Thrombus, Amelia Mellor, Abedayo Olusanya, Daniel Ortiz 2025 HCA Healthcare

A Rare Presentation Of Prothrombin G20210a Mutation As A Right Ventricular Thrombus, Amelia Mellor, Abedayo Olusanya, Daniel Ortiz

Central & West Texas and San Antonio GME Research Day 2025

No abstract provided.


When Leukemia Takes A Bite: Unusual Gastric Involvement In B-All, Supritha Chintamaneni, Bilal Ashraf, Sushovan Guha 2025 HCA Healthcare

When Leukemia Takes A Bite: Unusual Gastric Involvement In B-All, Supritha Chintamaneni, Bilal Ashraf, Sushovan Guha

Gulf Coast Division GME Research Day 2025

No abstract provided.


Mechanical Ground Level Fall With Incidental Findings Of Suspected Multiple Myeloma: A Case Report, Mohammed Irfan Khan, Jeffrey Lesser, Shuchita Jhaveri, Neethu George, Shai Ring, Kaylah Perez, Julian Nguyen 2025 HCA Healthcare

Mechanical Ground Level Fall With Incidental Findings Of Suspected Multiple Myeloma: A Case Report, Mohammed Irfan Khan, Jeffrey Lesser, Shuchita Jhaveri, Neethu George, Shai Ring, Kaylah Perez, Julian Nguyen

Gulf Coast Division GME Research Day 2025

No abstract provided.


Optimizing Opioid Selection For Vaso-Occlusive Crisis: Identifying The Best Option To Reduce Hospital Length Of Stay, Benjamin H. Bridges, Laura Strom, Eric Belcher, Winston Daniels, Ansley Connelly, Joshua Ferrell 2025 HCA Healthcare

Optimizing Opioid Selection For Vaso-Occlusive Crisis: Identifying The Best Option To Reduce Hospital Length Of Stay, Benjamin H. Bridges, Laura Strom, Eric Belcher, Winston Daniels, Ansley Connelly, Joshua Ferrell

South Atlantic Division GME Research Day 2025

No abstract provided.


Preliminary Validity Of A Daily Functional Status Pain Assessment Tool, Wally R. Smith, Rehan Qayyum, Alexandra Ulbing, Margaret S. Guy, Daniel M. Sop, Yue May Zhang 2025 Virginia Commonwealth University

Preliminary Validity Of A Daily Functional Status Pain Assessment Tool, Wally R. Smith, Rehan Qayyum, Alexandra Ulbing, Margaret S. Guy, Daniel M. Sop, Yue May Zhang

Department of Medicine Faculty Publications

Objectives: Readiness for discharge for a sickle cell disease vaso-occlusive crisis is dictated by factors far beyond pain control, including physical function/activity. We therefore designed and tested a functional status-based pain assessment questionnaire in SCD patients hospitalized with vaso-occlusive crises.

Methods: Sickle cell disease patients on a preselected nursing unit rated 10 draft Functional status-Based Pain Assessment items of activities of daily living on a 5 point Likert scale (0-5) from “very easy” to “very difficult” daily on each day of their admission until discharge, at approximately the same time. Concurrently, they reported Numeric Rating Scale (0-10) pain intensity. …


Pediatric Sickle Cell Pain Management: Effectiveness Of Non-Narcotic Interventions, Rebecca J. Giraldo, Chelsea Burke, Amaka Okere, RayQuan Brooks 2025 Kennesaw State University

Pediatric Sickle Cell Pain Management: Effectiveness Of Non-Narcotic Interventions, Rebecca J. Giraldo, Chelsea Burke, Amaka Okere, Rayquan Brooks

Master's Projects

Background: Frequent severe pain episodes are a common experience among children with Sickle Cell Disease (SCD). Pain management in SCD pediatric patients is challenging due to its subjective nature and inaccurate assessment of interventions. The difficulty in pain assessment poses a challenge to healthcare providers seeking to determine the appropriate use of narcotic medication, increasing the risk of addiction. Due to the potential adverse effects of narcotics and other narcotic medication in long-term pain management, non-narcotic interventions are rapidly emerging as treatment plans of choice.

Aim: This review aims to explore safe non-narcotic interventions pain management approaches to reduce reliance …


Digital Commons powered by bepress